LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Elenco Azioni・Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Co Ltd ADR

Chiusa

SettoreSettore sanitario

16.7 1.03

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

16.53

Massimo

16.75

Metriche Chiave
By Trading Economics
Entrata	117B 106B
Vendite	100B 1.2T
P/E Media del settore	75.273 49.8
EPS	0.21
Rendimento da dividendi	3.98
Margine di Profitto	8.697
Dipendenti	47,455
EBITDA	140B 456B

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+26.81% upside

Dividendi
By Dow Jones
Rendimento da dividendi Media del settore	3.98% 2.25%

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-3B 52B
Apertura precedente	15.67
Chiusura precedente	16.7

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

N/A / 15.16 Supporto e resistenza

Takeda Pharmaceutical Co Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 gen 2026, 07:11 UTC

Utili

Takeda Posts Sharply Higher Quarterly Profit, Raises Annual Guidance

19 dic 2025, 03:32 UTC

I principali Market Mover

Takeda Pharmaceuticals Shares Rise on Positive Psoriasis Treatment Results

30 ott 2025, 09:39 UTC

Utili

Takeda Swings to Loss on Impairment Charges, Cuts Guidance -- Update

30 ott 2025, 07:32 UTC

Utili

Takeda Posts Quarterly Net Loss, Cuts Guidance

21 ott 2025, 15:33 UTC

I principali Market Mover

Healwell AI Shares Rise on AI-Platform Demonstration

29 gen 2026, 06:53 UTC

Utili

Takeda Says Higher FY Revenue Forecast Due to Weaker Yen

29 gen 2026, 06:36 UTC

Utili

Takeda Raises FY Revenue, Net-Profit Views

29 gen 2026, 06:34 UTC

Utili

Takeda 3Q Net Profit Missed Y107.9B Expected in Poll of Analysts by Visible Alpha

29 gen 2026, 06:33 UTC

Utili

Takeda Pharmaceutical 3Q Rev Y1.192T Vs. Y1.144T >4502.TO

29 gen 2026, 06:32 UTC

Utili

Takeda Pharmaceutical 3Q Net Y103.6B Vs. Net Y23.8B >4502.TO

29 gen 2026, 06:30 UTC

Utili

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29 gen 2026, 06:30 UTC

Utili

Takeda Pharmaceutical 9-Mos Pretax Pft Y312.67B Vs Pft Y282.38B

29 gen 2026, 06:30 UTC

Utili

Takeda Pharmaceutical 9-Mos Oper Pft Y422.38B Vs Pft Y417.52B

29 gen 2026, 06:30 UTC

Utili

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29 gen 2026, 06:30 UTC

Utili

Takeda Pharmaceutical 9-Mos Rev Y3.41T Vs Y3.53T

29 gen 2026, 06:30 UTC

Utili

Takeda Pharmaceutical 9-Mos EPS Y137.31 Vs EPS Y133.71

30 ott 2025, 07:10 UTC

Utili

Takeda: 1H Core Business Results Were Consistent With Company's Expectations

30 ott 2025, 06:50 UTC

Utili

Takeda 2Q Net Loss Missed Y65.2B Profit Expected in Visible Alpha Poll of Analysts

30 ott 2025, 06:49 UTC

Utili

Takeda Pharmaceutical 2Q Rev Y1.113T Vs. Y1.176T >4502.TO

30 ott 2025, 06:48 UTC

Utili

Takeda Pharmaceutical 2Q Loss Y11.8B Vs. Net Y92.0B >4502.TO

30 ott 2025, 06:45 UTC

Utili

Takeda: Lowered Guidance Reflects Impairment Charges Associated With Strategic Pipeline Decisions

30 ott 2025, 06:42 UTC

Utili

Takeda Pharmaceutical Cuts FY Revenue, Net-Profit Views

30 ott 2025, 06:40 UTC

Utili

Takeda Pharmaceutical 1H Net Y112.44B Vs Net Y187.29B

30 ott 2025, 06:40 UTC

Utili

Takeda Pharmaceutical 1H Net Y112.44B Vs Net Y187.29B

30 ott 2025, 06:40 UTC

Utili

Takeda Pharmaceutical 1H Pretax Pft Y178.80B Vs Pft Y255.98B

30 ott 2025, 06:40 UTC

Utili

Takeda Pharmaceutical 1H EPS Y71.57 Vs EPS Y118.85

30 ott 2025, 06:40 UTC

Utili

Takeda Pharmaceutical 1H Oper Pft Y253.56B Vs Pft Y350.58B

30 ott 2025, 06:40 UTC

Utili

Takeda Pharmaceutical 1H Rev Y2.22T Vs Y2.38T

10 ott 2025, 15:13 UTC

Acquisizioni, Fusioni, Takeovers

J&J, Protagonist Have Existing Ties -- WSJ

10 ott 2025, 15:13 UTC

Acquisizioni, Fusioni, Takeovers

Protagonist Has Market Value Over $4B -- WSJ

Confronto tra pari

Modifica del prezzo

Takeda Pharmaceutical Co Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

26.81% in crescita

Previsioni per 12 mesi

Media 21 USD 26.81%

Alto 21 USD

Basso 21 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Takeda Pharmaceutical Co Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Takeda Pharmaceutical Co Ltd ADR - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

N/A / 15.16Supporto e resistenza

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bullish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.